Advanced

Delayed onset of ototoxic effects of gentamicin in patients with Meniére's disease

Magnusson, M LU ; Padoan, Serge; Karlberg, M LU and Johansson, R (1991) In Acta Oto-Laryngologica. Supplement 111(Suppl. 485). p.120-122
Abstract

In treatment of Meniére's disease, installations of gentamicin are continued until there are signs of disturbance of vestibular or cochlear function. However, since it has been demonstrated that gentamicin is eliminated slowly from the inner ear, a continuing ototoxic effect may be suspected. The present study aimed to investigate the delay of onset of symptoms of ototoxic effects. Five patients with Meniére's disease and disabling vertigo were treated with intratympanic installation of gentamicin. The patients received two installations at two consecutive days, after which the treatment was abated, although no patient showed any symptoms of affection of the vestibular or cochlear end organs. All patients, however, developed vertigo and... (More)

In treatment of Meniére's disease, installations of gentamicin are continued until there are signs of disturbance of vestibular or cochlear function. However, since it has been demonstrated that gentamicin is eliminated slowly from the inner ear, a continuing ototoxic effect may be suspected. The present study aimed to investigate the delay of onset of symptoms of ototoxic effects. Five patients with Meniére's disease and disabling vertigo were treated with intratympanic installation of gentamicin. The patients received two installations at two consecutive days, after which the treatment was abated, although no patient showed any symptoms of affection of the vestibular or cochlear end organs. All patients, however, developed vertigo and nystagmus beating toward the not treated ear within 3 to 5 days after the last installation. At 3 months and 1 year later, the treated ear showed no reaction on bithermal caloric stimulation and all patients had a complete relief of attacks of vertigo but hearing levels were about the same compared to before treatment. The present findings demonstrate a delayed onset of ototoxic effects and it is suggested that gentamicin treatment should not be carried on until symptoms develop. Furthermore, extremely low dose treatment may produce loss of vestibular function with the desired relief of vertigo and with less hazards of affecting the hearing level.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adult, Audiometry, Pure-Tone, Caloric Tests, Cochlea, Electrooculography, Female, Gentamicins, Humans, Injections, Spinal, Labyrinth Diseases, Male, Meniere Disease, Middle Aged, Speech Perception, Vertigo, Journal Article, Research Support, Non-U.S. Gov't
in
Acta Oto-Laryngologica. Supplement
volume
111
issue
Suppl. 485
pages
3 pages
publisher
Scandinavian University Press
external identifiers
  • pmid:1843163
  • scopus:0026360066
ISSN
0365-5237
DOI
10.3109/00016489109128051
language
English
LU publication?
yes
id
41664222-b70b-4ba7-8af9-9dc194e4dbe6 (old id 1105630)
date added to LUP
2008-08-01 14:55:16
date last changed
2017-06-08 11:16:02
@article{41664222-b70b-4ba7-8af9-9dc194e4dbe6,
  abstract     = {<p>In treatment of Meniére's disease, installations of gentamicin are continued until there are signs of disturbance of vestibular or cochlear function. However, since it has been demonstrated that gentamicin is eliminated slowly from the inner ear, a continuing ototoxic effect may be suspected. The present study aimed to investigate the delay of onset of symptoms of ototoxic effects. Five patients with Meniére's disease and disabling vertigo were treated with intratympanic installation of gentamicin. The patients received two installations at two consecutive days, after which the treatment was abated, although no patient showed any symptoms of affection of the vestibular or cochlear end organs. All patients, however, developed vertigo and nystagmus beating toward the not treated ear within 3 to 5 days after the last installation. At 3 months and 1 year later, the treated ear showed no reaction on bithermal caloric stimulation and all patients had a complete relief of attacks of vertigo but hearing levels were about the same compared to before treatment. The present findings demonstrate a delayed onset of ototoxic effects and it is suggested that gentamicin treatment should not be carried on until symptoms develop. Furthermore, extremely low dose treatment may produce loss of vestibular function with the desired relief of vertigo and with less hazards of affecting the hearing level.</p>},
  author       = {Magnusson, M and Padoan, Serge and Karlberg, M and Johansson, R},
  issn         = {0365-5237},
  keyword      = {Adult,Audiometry, Pure-Tone,Caloric Tests,Cochlea,Electrooculography,Female,Gentamicins,Humans,Injections, Spinal,Labyrinth Diseases,Male,Meniere Disease,Middle Aged,Speech Perception,Vertigo,Journal Article,Research Support, Non-U.S. Gov't},
  language     = {eng},
  number       = {Suppl. 485},
  pages        = {120--122},
  publisher    = {Scandinavian University Press},
  series       = {Acta Oto-Laryngologica. Supplement},
  title        = {Delayed onset of ototoxic effects of gentamicin in patients with Meniére's disease},
  url          = {http://dx.doi.org/10.3109/00016489109128051},
  volume       = {111},
  year         = {1991},
}